Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
marialaura.bisegna@uniroma1.it
Maria Laura Bisegna
Assegnista di ricerca
Struttura:
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
E-mail:
marialaura.bisegna@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
INTEGRATION OF CD200, CD43 AND ROR1 IN MULTIPARAMETER FLOW CYTOMETRY (MFC) ROUTINE PANELS FOR THE DIFFERENTIAL DIAGNOSIS OF B-CELL LYMPHOPROLIFERATIVE DISORDERS (B-LPDS)
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2025
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib
ONCOLOGY AND THERAPY
2025
A novel complex mutation in the exon 9 of CALR gene: p.E381fs*52 (gagg_CCTCTTTGCCTC)
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE
2025
T-cell Receptor (TCR)-Vβ Repertoire Flow Cytometry for T-cell Lymphoproliferative Disorder: a Retrospective Analysis of a Single-Center Real-Life Laboratory Experience
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2025
CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITDmut -AML): a flow-cytometric marker for an accurate diagnostic workup
LEUKEMIA & LYMPHOMA
2025
Baseline, Drug‐Related and Persistent Anemia and/or Thrombocytopenia Predict Responses and Prognosis in Myelofibrosis Patients Treated With Ruxolitinib
HEMATOLOGICAL ONCOLOGY
2025
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
EUROPEAN JOURNAL OF HAEMATOLOGY
2024
Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
FRONTIERS IN ONCOLOGY
2024
Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia
JOURNAL OF CLINICAL MEDICINE
2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety
EXPERT OPINION ON DRUG SAFETY
2024
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors
EXPERT OPINION ON PHARMACOTHERAPY
2024
Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukemia
CANCERS
2024
NG2 molecule expression in acute lymphoblastic leukemia B cells: a flow-cytometric marker for the rapid identification of KMT2A gene rearrangements
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2024
CD146 MOLECULE EXPRESSION IN B CELLS ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALLs): A FLOW- CYTOMETRIC MARKER FOR AN ACCURATE DIAGNOSTIC WORK-UP
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
2024
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML)
EXPERT REVIEW OF HEMATOLOGY
2024
Management of Chronic Myeloid Leukemia Patients in Later Lines: The Role of Ponatinib and New Compounds
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2023
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients
EXPERT REVIEW OF HEMATOLOGY
2022
Trapianto di cellule staminali
Ematologia Smart, Edizioni Idelson Gnocchi 1908
2022
Diagnostica di laboratorio e strumentale
Ematologia Smart, Edizioni Idelson Gnocchi 1908
2022
1
2
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma